A genetic medicine from Ionis Pharmaceuticals designed to reduce high levels of cholesterol has achieved the main goal of a Phase 2 study, but the results are short of what partner AstraZeneca hoped ...
Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired exclusive global rights from IONS to develop and market sapablursen, an ...
Shares of Ionis Pharmaceuticals (IONS Quick Quote IONS - Free Report) rose nearly 5% in after-market trading on Thursday after the FDA approved its RNA-targeted therapy, olezarsen, in adults with ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals won approval from the Food and Drug Administration on ...
Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Illustration shows a test tube in front of displayed Biogen logo (Reuters) - Biogen and Ionis Pharmaceuticals said on ...
Jan 22 (Reuters) - Ionis Pharmaceuticals (IONS.O), opens new tab said on Monday its experimental drug reduced the occurrence of painful attacks in patients with a rare genetic disease that triggers ...
Initial findings from a Phase 3 efficacy trial suggest Ionis Pharmaceuticals’ RNA-targeted treatment, given monthly or bimonthly, cut angioedema attacks more than placebo, the firm said Monday. The ...
Narrow-moat Ionis’ third-quarter results are in line with our expectations. We are maintaining our $69 fair value estimate, and we believe the company is ready for its first two independent US drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results